邵幼雲 醫師

臺大醫院腫瘤醫學部

Dual Immune Checkpoint Blockade for Advanced Hepatocellular Carcinoma


1. Adding anti-CTLA4 antibody to PD1 blockade improves treatment response of advanced HCC
2. Nivolumab + ipilimumab has been approved for patients after sorafenib treatment failure in USA
3. Management of adverse events is crucial for using dual CTLA4 and PD1 blockade
4. Whether dual CTLA4 and PD1 blockade can be used as first-line therapy for advanced HCC remained to be explored

相關資訊

提升醫療品質

Promoted to the medical quality

台灣肝癌醫學會 (TLCA)
Leave a comment

各位會員您好,如果您針對活動內容有任何想法,歡迎留下您的回饋與建議,我們將依據您們的回饋來調整接下來幾集的影片內容,謝謝您對學會的支持與指教。

留言功能僅在新影片上傳後三天內開啟。

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.